Thursday, 29 October 2026 Every NSE & BSE announcement, by company
ALFA Filings Every announcement, straight from the exchange
Business Update

Bharat Parenterals Business Update

Bharat Parenterals Limited's subsidiary, Innoxel Lifesciences, concluded a U.S. FDA inspection at its Vadodara facility with five procedural observations under a Voluntary Action Indicated (VAI) classification. The inspection occurred in April 2026. The company maintains its commitment to quality standards and will submit responses within prescribed timelines.

Source

BSE filing, NSE: BPLPHARMA. Summary written from the filing by ALFA Finder's alert engine.

Read the filing ↗

Bharat Parenterals Ltd: key numbers

Share price
₹1,918.70
Market cap
₹1,322 Cr
Revenue (annual)
₹345.4 Cr
Net profit (annual)
₹-8.19 Cr
P/E (TTM)
-85.8×Sector 46.1×
Promoter holding
67.20%+0.00% QoQ
FII holding
0.11%Current quarter

Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.

More from Bharat Parenterals Ltd

All →

Other business update announcements

All →